Phaseline

Companies › Arctic Therapeutics

Arctic Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Caficrestat (NPI-001)
Aldose reductase inhibitor
AKR1B1Phase 2Hereditary Cystatin C Amyloid Angiopathy (HCCAA)Dec 2026
NPI-001 (AT-001)–Phase 2Alzheimer´s DiseaseApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07716865Caficrestat (NPI-001)Phase 2Hereditary Cystatin C Amyloid Angiopathy (HCCAA)NeurologyDec 2026
NCT07741526NPI-001 (AT-001)Phase 2Alzheimer´s DiseaseNeurologyApr 2027

Targets

AKR1B1 (1)

Companies with the same targets

Applied Therapeutics

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.